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Pancreatic islet transplantation is a promising option for the treatment of type 1 diabetic patients. After the successful
demonstration of the Edmonton protocol, islet transplantation has advanced signiﬁcantly on several fronts, including improved
pancreas procurement and preservation systems. Since we frequently use pancreata from donors after cardiac death in Japan,we
have applied the in situ regional organ cooling system for pancreas procurement to reduce the warm ischemic time. To reduce the
apoptosis of pancreatic tissue during cold preservation, we have applied the ductal injection of preservation solution. For pancreas
preservation, we use modiﬁed Kyoto solution, which is advantageous at trypsin inhibition and less collagenase inhibition. In this
paper, we show pancreas procurement and preservation in our group for islet transplantation.
1.Introduction
Diabetes mellitus is a devastating disease, and over 200
million people are aﬀected worldwide, thus representing
about 6% of the world population. Type 1 diabetes results
from the autoimmune-mediated destruction of insulin-
secreting β cells in the islets of Langerhans of the pancreas.
Pancreatic islet transplantation represents a viable option for
the treatment of patients with unstable type 1 diabetes mel-
litus with frequent severe hypoglycemia and hypoglycemia
unawareness [1, 2]. Recent advances in islet transplantation,
includingtheutilizationofdonorsaftercardiacdeath(DCD)
[3–6], single-donor islet transplantation [7–10], and living-
donor islet transplantation [11] ,w e r eb a s e do na d v a n c e d
pancreas transport systems [9, 12, 13], improved islet isola-
tion methods [14–17], enhanced islet engraftment [18–21],
and revised immunosuppressant protocols [6, 14, 22]. One
of the most important issues aﬀecting islet transplantation
is concerned with donor quality [23]. Several critical donor
factors have been identiﬁed, including donor age, body mass
index (BMI), cause of death, usage of vasopressor, hypoten-
sive episode, length of hospitalization, blood glucose levels,
transaminases level, creatinine levels, cold preservation time,
andprocurementteam[23–26].Therefore,eﬀectivepancreas
procurement and preservation are important for successful
islet isolation and transplantation. In this paper, the current
advances in pancreas procurement and preservation for islet
transplantation in our group are described.
2. Pancreas Procurement
Pancreata from donors with brain death (DBD) are procured
using a standardized technique to minimize warm ischemia.
A preservation solution, such as the University of Wisconsin
(UW) solution, is used for in situ perfusion of the donor.
The human pancreas is excised immediately after the liver
and before the kidneys. The ﬁrst and fourth portions of
the duodenum are ﬁrst divided with a 55mm linear cutter.
The attachment between the retroperitoneal portion and the
body of the pancreas is then dissected toward the spleen. The
superior surface of the pancreas is divided toward the spleen,
and the short gastric arteries and vein are dissected until the
stomach is separated from the spleen. The pancreas is then
rapidly excised en bloc together with the spleen. The spleen
and duodenum are subsequently removed on a back table,
and a cannula is inserted into the main pancreatic duct.
Currently, only a few clinical studies have reported
that islet transplantation from DCD is possible to treat
type 1 diabetes [27, 28]. Vasopressors are used for most2 Journal of Transplantation
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Figure 1: Pancreas procurement and preservation for islet trans-
plantation. (a) In situ regional cooling system to DCD pancreata.
(b) Ductal injection of preservation solution. (c) Pancreas preser-
vation by MK solution/PFC two-layer method.
DCDs, and they tend to have hypotensive episodes, long
term hospitalization, and high levels of blood glucose,
transaminases, and creatinine which have been identiﬁed as
critical factors that aﬀect the quality of the pancreas [23–26].
Islet transplantation from DCD is particularly important
for countries such as Japan, where the isolation of islets
from pancreata of donors who are classiﬁed as brain-dead
but whose hearts are beating is prohibited by law. We
developed the novel procurement technique in collaboration
with the kidney procurement team [29]. After conﬁrmation
of brain death, a double-balloon catheter is inserted to
prevent ischemic damage to the human pancreas by using
an in situ regional organ cooling (ISRC) system that was
originally developed for procurement of the kidney [30].
Before cardiac arrest, a tip of the double-balloon catheter
is placed above the celiac axis in the aorta via the femoral
artery and only a few centimeters above the location used for
an ordinary nephrectomy for procurement from a DCD. A
venous catheter is also placed in the inferior vena cava via
the femoral vein for drainage of the perfusate and blood.
ISRC for the pancreas and kidney (ISRC-PK) is achieved
by pump or drip infusion (drip speed 20mL/min) of a
hypothermic lactated ringer solution beginning immediately
after cardiac arrest and then continuing until the end of
the nephrectomy and pancreatectomy. After laparotomy, the
lesser sac is opened by dividing the gastrocolic and gastro-
hepatic ligaments to determine whether the pancreas has
uniform perfusion eﬃcacy by means of ISRC-PK. Perfusion
of the pancreas is evaluated by the uniform color change of
the pancreas and the coldness of the pancreas surface after
laparotomy. After a visual check of the pancreas, 500mL of
sterile crushed ice is placed on it to avoid warm ischemic
injury and then the pancreas is harvested (Figure 1(a)) [29].
The ISRC system was originally developed for the
procurement of the kidney [30], and the only modiﬁcation
we made is the position of the double-balloon catheter to
ensure both pancreas and kidney protection. This ISRC
system reduced the warm ischemic time to only 3 minutes
on average [29]. We have used lactate ringer solution
instead of UW solution for perfusion. Lactate ringer solution
has a low potassium concentration and low viscosity in
comparison to UW solution. A low potassium concentra-
tion could prevent potassium-induced vasospasms while a
low viscosity helps to induce rapid perfusion. Therefore,
using lactate ringer for perfusion might be important in
ISRC.
3. DuctalInjection of PreservationSolution
We previously developed a new method for large-scale
porcine islet isolation from market-weight pigs [31], based
on a report by O’Neil et al. [32]. Although some steps of
the new method seemed technically inferior to the standard
automated method using a Ricordi chamber, islet yield per
gram for our new method was relatively higher (but not
signiﬁcantly so) than that for the Ricordi method [33]. It
is possible that the advantage of the new method was the
injection of 1.0–1.5mL/g pancreas of UW-D (UW solution
with high Na+/low K+) solution. It was also shown that islet
yields from pancreata with intraductal ﬂush, along with col-
lagenasepriortopreservation,weresuperiortovascularﬂush
[34]. We speculate that the ductal injection of a large volume
of preservation solution (1mL/g pancreas) may improve the
islet yield. We investigated whether ductal injection (UW
and modiﬁed Kyoto (MK) solution) before pancreas storage
improves the islet yields in islet isolation using porcine
pancreata. After obtaining the pancreas, we immediately
inserted a cannula into the main pancreatic duct, infused
a large amount of preservation solution (1mL/g pancreas)
for ductal protection, and placed the pancreas into a preser-
vation container (Figure 1(b)). The islet yield both before
and after puriﬁcation was signiﬁcantly higher in the ductal
injection group than in the control group. The TUNEL-
positive cells in the ductal injection group signiﬁcantly
decreased in comparison to the control group. The ductal
injection of preservation solution increased the ATP level
in the pancreas tissue and reduced trypsin activity during
the digestion step. In a transplant model, ductal injection
improved the islet graft function. These ﬁndings suggest
that the ductal injection of preservation solution leads to
improved outcomes for pancreatic islet transplantation [35].
Another group also showed the ductal injection of a small
volume (0.05–0.1mL/g) of UW solution at the time of
pancreasprocurementtoimprovetheisletyieldandfunction
in a rodent model [36]. Based on these data, we now use
this technique for clinical islet transplantation. With this
technique,werarelyseeclumpingorDNArelease,evenusing
D C D ,a n dw en e v e ru s eD N a s e .
4. PreservationSolution
UW solution has been recognized as the gold standard
solution for organ preservation. UW solution is used exten-
sively as a cold storage solution during procurement and
transport of the pancreas prior to islet isolation. However,Journal of Transplantation 3
UW solution has several disadvantages: it must be stored in
the cold until use, and its short shelf life makes it expensive.
It is also highly viscous, which may complicate the initial
organ ﬂush [37]. For islet isolation, it has been observed
that UW inhibits the collagenase digestion phase of islet
isolation, thus resulting in poor islet yields and islets of
poor viability [38, 39]. It has been reported that the com-
ponents in UW solution found to be most inhibitory were
magnesium, low Na+/high K+, hydroxyethyl starch (HES),
and adenosine. Furthermore, previous reports also indicated
that allopurinol in combination with either lactobionate
or glutathione markedly inhibited collagenase and that the
most inhibitory solution tested was a combination of three
components, raﬃnose, glutathione, and lactobionate [39].
We evaluated the eﬀect of MK solution for islet isolation
[12]. Kyoto University developed the ET-Kyoto solution, and
its eﬀectiveness in cold lung storage has been demonstrated
in clinical lung transplantation [40, 41]. It also is eﬀective
for skin ﬂap storage, and its clinical application is beginning
in this ﬁeld [42]. MK solution is a modiﬁed ET-Kyoto
solution,inwhichulinastatinisadded.MKsolutioncontains
trehalose, gluconate, and ulinastatin as distinct components.
Trehalose has a cytoprotective eﬀect against stress, and
g l u c o n a t ea c t sa sa ne x t r a c e l l u l a ro n c o t i ca g e n t ,w h i c h
prevents cells from swelling [44]. Ulinastatin is a trypsin
inhibitor and eliminates trypsin activity during pancreas
preservation [12]. Due to the chemical stability of the
eﬀective components and other ingredients, MK solution,
but not UW solution, can be stored at room temperature
for a long period. MK solution has high Na+/low K+,a n d
it includes only HES at a lower concentration than UW
solution, thus suggesting a lower collagenase inhibition than
UW solution. It has also been shown that the Na+/K+ ratio,
adenosine, allopurinol, and glutathione are not essential for
the coldstorage ofpancreatic digestprior toislet puriﬁcation
[45]. Moreover, trehalose and ulinastatin inhibit collagenase
digestion less than UW solution [12]. The high potassium
concentrationinUWsolutioncausesvasospasmsandinsulin
release from pancreatic β cells [46], and the high viscosity
of UW solution may thus prevent suﬃcient ﬂushing and
ductal injection. In both porcine and human islet isolation,
the islet yield was signiﬁcantly higher in the MK group
compared with the UW group [12, 47]. These ﬁndings
show that MK solution is a more eﬀective cold-storage
solution in pancreas preservation for islet isolation than UW
solution.
We next compared histidine-tryptophan-ketoglutarate
(HTK) solution and MK solution for islet isolation. HTK
solution was originally developed for cardioplegia and is
being used with increasing frequency in cardiac, renal, and
hepatic transplantation [48, 49]. The protective eﬀect of
HTK solution is based on the strong buﬀering capacity of
histidine. This solution has a low viscosity, easy handling
properties, and a relatively low cost. Some studies have
demonstrated similar results between UW and HTK solu-
tions for pancreas preservation, in not only experimental
animal models [43, 50, 51] but also clinical pancreas trans-
plantation [52–54]. We used HTK solution with ulinastatin
(modiﬁed HTK solution (M-HTK)) in this study because
MK solution includes ulinastatin. In porcine islet isolation,
the islet yield after puriﬁcation was signiﬁcantly greater in
the MK group than in the M-HTK group. The MK group
had a signiﬁcantly higher ATP level in the islets than in the
M-HTK group. These data suggest that MK solution is better
for pancreas preservation before islet isolation than M-HTK
solution [55]. The M-HTK solution includes magnesium
but does not include HES, adenosine, allopurinol, lacto-
bionate, glutathione, or raﬃnose. There are no signiﬁcant
diﬀerences between the MK and M-HTK solutions regarding
collagenase activity. Therefore, the diﬀerent islet yields
after puriﬁcation are not due to diﬀerences in collagenase
inhibition between these two solutions. Since a signiﬁcantly
higher ATP level in islets was observed in the MK group
compared to the M-HTK group, the cytoprotective eﬀect
such as HES and/or trehalose might be a factor in the
islet yield diﬀerences observed between the two solutions.
Another group recently reported that, compared with UW
solution, HTK solution has similar eﬃciency for preserving
human pancreata for subsequent islet isolation during <10h
cold ischemia time, but prolonged cold storage resulted in a
reduced islet yield [56].
Recently, Celsior solution has been used as an alternative
solution for organ preservation. Celsior is an extracellular
solution deprived of colloid and was initially developed for
heart preservation [57]. Preliminary clinical studies showed
no diﬀerences between UW and Celsior for lung [58], liver
[59], and kidney [60] preservation. Hubert et al. recently
reported on the application of Celsior solution for in situ
perfusion of the donor before human and pig islet isolation
[61]. Their data showed the in situ perfusion of UW solution
to be superior to Celsior solution. In contrast to UW, Celsior
induced cell swelling and pancreas edema after only four
hours of cold storage. The components of Celsior solution
are in part similar to MK solution (a high-sodium/low-
potassium composition with comparatively low viscosity)
and in part similar to UW solution (including lactobionate
acid and glutathione). We next compared modiﬁed Celsior
solution(CelsiorsolutionwithHESandnafamostatmesilate,
HNC) and MK solution [47]. Since Celsior solution lacks
HES, which is an oncotic agent and protects cell swelling,
we added HES to Celsior solution in this study. We also
added nafamostat mesilate, one of the trypsin inhibitors,
to Celsior because one of the advantages of MK solution is
trypsin inhibition by ulinastatin. Nafamostat mesilate has a
higher level of trypsin inhibition than ulinastatin [62, 63].
In human islet isolation, the islet yield after puriﬁcation was
signiﬁcantlyhigherintheMKgroupthanintheHNCgroup.
The HNC group had a longer phase I period (digestion
time), a higher volume of undigested tissue, and a higher
percentage of embedded islets, thus suggesting that the
solution may inhibit collagenase. However, there was no
signiﬁcant diﬀerence in the ATP content in the pancreata
or in the attainability of posttransplant normoglycemia in
diabetic nude mice between the two groups, thus suggesting
that the quality of islets was similar between the two groups.
These data suggest that MK solution is better for pancreas
preservationbeforeisletisolationthanHNCsolution(Tables
1 and 2).4 Journal of Transplantation
Table 1: Composition and other characteristics of each preserving
solution.
ET-K MK UW HNC M-HTK
Na (mmol/L) 100 100 29 100 15
K (mmol/L) 43.5 43.5 125 15 10
Mg (mmol/L) — — 5 13 4
Ca (mmol/L) — — — 0.25 0.015
Cl (mmol/L) — — — 41 50
Gluconate (mmol/L) 100 100 — — —
Phosphate (mmol/L) 25 25 25 — —
Sulfate (mmol/L) — — 5 — —
Lactobionate (mmol/L) — — 100 80 —
Raﬃnose (mmol/L) — — 30 — —
Trehalose (mmol/L) 120 120 — — —
Adenosine (mmol/L) — — 5 — —
Alloprinol (mmol/L) — — 1 — —
Glutathione (mmol/L) — — 3 3 —
HES (g/L) 30 30 50 30 —
Ulinastatin (×103 U/L) — 100 — — 100
Nafamostat mesilate (mg/L) — — — 20 —
Histidine (mmol/L) — — — 30 198
Mannitol (mmol/L) — — — 60 30
α-ketoglutarate (mmol/L) — — — — 1
Tryptophan (mmol/L) — — — — 2
Glutamic acid (mmol/L) — — — 20 —
Osmolality (mOsm) 366 366 320 355 310
HES: hydroxyethyl starch; ROS: reactive oxygen species; ET-K: ET-Kyoto
solution; MK: modiﬁed ET-Kyoto solution; UW: University of Wisconsin
solution; HNC: Celsior solution with HES and nafamostat mesilate; M-
HTK: modiﬁed histidine-tryptophan-ketoglutarate solution.
Table 2: Comparison between the diﬀerent preservation solutions.
Comparison Superior Human/animal
study Reference
MK versus UW MK Porcine [12]
MK versus UW MK Human [41]( i n
discussion)
MK versus ET-K MK Rat [12]
MK versus
M-HTK MK Porcine [43]
MK versus HNC MK Human [41]
UW: University of Wisconsin solution;MK: modiﬁed ET-Kyoto solution
(ET-Kyoto solution with ulinastatin); ET-K: ET-Kyoto solution; M-HTK:
modiﬁed histidine-tryptophan-ketoglutarate solution (HTK solution with
ulinastatin); HNC: Celsior solution with HES and nafamostat mesilate.
5. TrypsinInhibitors in PreservationSolution
Trypsin from pancreatic acinar cells destroys islets. Previ-
ous study has shown that trypsin inhibition by Pefabloc
during human pancreas digestion improves islet yield and
reduces the fraction of embedded (trapped) islets [64],
thus suggesting that trypsin may degrade the ductules and
thus reduce the delivery of collagenase solution to tissue
around the islets. We previously reported that pancreas
Table 3: Trypsin inhibitors in ET-Kyoto solution.
Trypsin Isle yield Viability SI∗
Trypsin
inhibitors inhibition versus
ulinastatin
versus
ulinastatin
versus
ulinastatin
Ulinastatin ++ — — —
Pefabloc + Lower n.s. Lower
Gabexate
mesilate +++ n.s. Lower Lower
Nafamostat
mesilate ++++ n.s. Lower n.s.
∗Stimulation index; n.s.: not signiﬁcant.
preservation using MK solution including ulinastatin, which
eliminated trypsin activity during pancreas preservation,
was superior to that using ET-Kyoto solution without the
trypsin inhibitor in a rat model [12]. Furthermore, the
advantages of MK solution are its trypsin inhibition and less
collagenase inhibition in human and porcine islet isolation
[12, 47]. Therefore, we compared ulinastatin with other
trypsininhibitors,including Pefabloc,gabexatemesilate,and
nafamostat mesilate, in preservation solution for porcine
islet isolation [62, 63]. Trypsin inhibition is greater in ET-
Kyoto with gabexate mesilate (GK) solution and ET-Kyoto
withnafamostatmesilate(NK)solutionthaninMKsolution.
The islet yield before puriﬁcation was higher in the MK
group than in the ET-Kyoto with Pefabloc (PK) group.
Viability was higher for the MK group than for either the GK
group or the NK group. The stimulation index was higher
for the MK group than for either the PK group or the GK
group. These data suggest that MK solution was synthetically
superior to the PK, GK, or NK solutions, although trypsin
inhibition is greater in GK and NK solutions than in MK
solution (Table 3)[ 62, 63], possibly due to diﬀerences of
inhibitory eﬀects of cytokines. Ulinastatin has been shown
to inhibit not only trypsin activity but also the release of
neutrophil elastase. It also downregulates transcription of
TNF mRNA, the activation of endothelial cells, and the
expression of ICAM-1 induced by endotoxin in vitro [65–
67]. The administration of ulinastatin has been shown to
decrease ischemia-reperfusion injury [68] or attenuate the
elevation in the concentrations of inﬂammatory cytokines
and C-reactive protein, a marker of inﬂammation [69], in
the transplanted small intestine.
Recently, the importance of tryptic-like activity (TLA)
obtained from Clostridium histolyticum in collagenase NB1
with neutral protease for eﬃcient islet isolation was demon-
strated [70]. Enhancing TLA resulted in a signiﬁcant
reduction of recirculation time and incrementally increased
human islet yield. The clostridial TLA and pancreatic trypsin
seemed to be diﬀerent in their speciﬁcity toward islet and
nonislet pancreatic tissue because no detrimental eﬀect on
islet viability and integrity was detected on clostridial TLA. If
trypsininhibitorsinhibitclostridialTLAaswellaspancreatic
trypsin, then they may inhibit pancreas digestion. This may
explain the synthetic superiority of MK solution to PK, GK,
or NK solutions, although trypsin inhibition is greater in GK
and NK solutions than in MK solution (Figure 1(c)).Journal of Transplantation 5
6.Two-LayerMethod
The two-layer preservation method (TLM), which uses
the concept of normobaric oxygenation comprising a cold
organ preservation solution (UW solution) with a perﬂuo-
rochemical (PFC) oxygen carrier solution, with the pancreas
being suspended between the two immiscible layers, has
been utilized for many clinical trials of islet transplantation
[71–74]. However, two recent large-scale studies showed
no beneﬁcial eﬀect of TLM, compared with UW storage,
on human islet isolation and transplantation [75, 76]. We
reevaluated the eﬀect of TLM using three diﬀerent groups:
group 1: UW simple storage; group 2: TLM performed
by multiorgan procurement teams (not specialists in islet
isolation); group 3: TLM performed by specialists in islet
isolation. There were no signiﬁcant diﬀerences between
group 1 and 2, whereas islet yields were signiﬁcantly higher
f o rg r o u p3c o m p a r e dw i t he i t h e rg r o u p s1o r2 .O u rd a t a
suggest that performance of TLM by experts could improve
the outcome of islet isolation and transplantation [71].
On the other hand, Papas et al. showed that the oxygen
penetration depth is about 1mm, suggesting that pancreas
oxygenation is limited during preservation with the TLM
[77]. In other words, their data suggest that the percentage of
pancreas oxygenation by TLM depends on its thickness and
the trimming of the pancreas before preservation by TLM is
thus considered to be important for pancreas oxygenation.
7. Conclusion
ET-Kyoto with ulinastatin was the best combination for
pancreas preservation in our studies. Since one of the
advantages of MK solution is less collagenase inhibition in
islet isolation, it is also suitable for ductal injection. Based on
these data, we now use the in situ regional cooling system
for DCD pancreata, the ductal injection of preservation
solution, and pancreas preservation by MK solution during
clinical islet isolation/transplantation. The in situ regional
cooling system to DCD pancreata, ductal injection, and
preservation by MK solution is therefore considered to
be useful improvement that may help to increase organ
utilization and thereby achieve good outcomes after islet
transplantation.
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